 DUBLIN, IRELAND and LITTLE FALLS, N.J, Jan. 12, 2021 GLOBE NEWSWIRE -- STERIS plc NYSE: STE STERIS or the Company and Cantel Medical Corp NYSE:CMD Cantel today announced that STERIS has signed a definitive agreement to acquire Cantel, through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers. Under the terms of the agreement, STERIS will acquire Cantel in a cash and stock transaction valued at 84.66 per Cantel common share, based on STERISs closing share price of 200.46 on January 11, 2021. This represents a total equity value of approximately 3.6 billion and a total enterprise value of approximately 4.6 billion, including Cantels net debt and convertible notes. The agreement has been unanimously approved by the Boards of Directors of both companies. 